TY - JOUR T1 - Sequential monitoring of leprosy patients with serum antibody levels to phenolic glycolipid-I, a synthetic analog of phenolic glycolipid-I, and mycobacterial lipoarabinomannan. AU - Meeker,H C, AU - Schuller-Levis,G, AU - Fusco,F, AU - Giardina-Becket,M A, AU - Sersen,E, AU - Levis,W R, PY - 1990/9/1/pubmed PY - 1990/9/1/medline PY - 1990/9/1/entrez SP - 503 EP - 11 JF - International journal of leprosy and other mycobacterial diseases : official organ of the International Leprosy Association JO - Int J Lepr Other Mycobact Dis VL - 58 IS - 3 N2 - Sequential serum samples from leprosy patients at various stages of antibacterial treatment were tested by an ELISA for antibodies to phenolic glycolipid I (PGL-I), a synthetic PGL-I analog (ND-BSA), and lipoarabinomannan (LAM) from Mycobacterium tuberculosis to determine if these antibodies could be useful in monitoring response to therapy. Among patients with positive initial anti-PGL-I IgM, a significant decrease in this antibody was seen over time (p less than 0.01), whether assayed by PGL-I or ND-BSA. The two antigens showed good agreement in the detection of decrease in anti-PGL-I IgM. The greatest decrease was seen in patients with a high initial anti-PGL-I IgM and a high bacterial index (BI). Patients with a declining BI were seen to have generally declining antibody levels to PGL-I and to LAM; in those patients with a fluctuating BI, antibody levels were less predictable. We conclude that antibodies to PGL-I and LAM can be useful in following response to therapy in leprosy patients and that either the native PGL-I or ND-BSA can serve as antigen for the ELISA. SN - 0148-916X UR - https://www.unboundmedicine.com/medline/citation/2205685/Sequential_monitoring_of_leprosy_patients_with_serum_antibody_levels_to_phenolic_glycolipid_I_a_synthetic_analog_of_phenolic_glycolipid_I_and_mycobacterial_lipoarabinomannan_ DB - PRIME DP - Unbound Medicine ER -